"In the field of biomedicine, there is limitless space for innovation, and innovation is the best time for us to innovate and improve the quality of life for everyone." On November 29, with the founder of Free Forum, Beijing) Bioengineering Technology Co., Ltd. Cheng Zengjiang, chairman of the "Financial" Annual Meeting 2018: Forecast and Strategy, "so said.
With the deliberate forum founder, Ke Beiyuan (Beijing) Biomedical Technology Co., Ltd. Cheng Zengjiang
Cheng Zengjiang said that when the research and development of new drugs get enough rewards, it has the possibility of sustainable development. In the area of drug research and development, we have too much space.
He also pointed out that the consistency assessment is indeed too important because generics solve the basic problem of most of our medication. It must be done, but the reality is also facing great difficulties. When we raise the standard, we will surely guide the enterprises to work hard in this direction. In a matter of years, our generic drugs have really reached the standard. After reaching, there will be a market.
The following is his speech record:
Cheng Zengjiang: I met many returnees entrepreneurs who came back to do the slogan of innovative medicine. They are innovative medicines that Chinese people can afford. This is a personal feeling and a policy environment in China. If we make a Hepatitis B drug, a curative drug, for $ 100, should we object or encourage? Should be encouraged. When the research and development of new drugs get enough rewards, it has the possibility of continuous development. In the area of drug research and development, we have too much space, unlike other industries, once satisfied, there is not much innovation. But in the field of medicine, we have too many diseases that can not be cured, we have too many diseases that can be treated but the effect is not good, or the side effects are too large, or the medication is very inconvenient. If we make innovations in these areas, and this innovation can be rewarded, we should encourage it.
A few years ago, because of the policy, some burden was incurred and backlog of generic drugs was produced. Why backlog it? Because there is no innovative atmosphere, there is no innovation return. Now the awareness of innovation has been formed, are looking for technical experts and innovative direction. Previous trial drug more trial of things, not medicine. In 2005, there was a shortage of people who were more likely to be cheated in medicine. From 2005 to 2010, there was a shortage of people who were analyzed. After 2010, there was a shortage of people who made preparations. In the future, it is necessary to make clinical shortages because this time of registration The approaches all point to how to do clinically valuable drugs. Therefore, the direction has changed. In particular, the two new initiatives on October 8 this year have resolved all aspects of our innovation. What we lack most now is talent, not capital, I met a lot of investors, feel that there is no project to vote, there is no good team. In recent years, some scientists came back from other countries one after another to start their own businesses. However, there is still not enough room for the strength and policies that the capital can support nowadays. This process can be solved with less than one click. If the payment side in the future to solve well, not just a matter of livelihood, but an industry thing, maybe our innovation is a very fast thing.
To put it simply, the consistency assessment is really important because generics solve the fundamental problem of most of our medication and it must be done, but the reality faces great difficulties. When we raise the standard, we will surely guide the enterprises to work hard in this direction. In a matter of years, our generic drugs have really reached the standard. After reaching, there will be a market.
Jin Liping: Well, because of the time, there is no way to invite the audience in the scene to participate in the interaction. Technological progress is ultimately about serving people, eventually going to treatment ports, advanced pharmaceuticals, and medical devices. I agree with this that disruptive technologies can profoundly change the original It is worth the wait that humankind overcome solidarity. Due to the time, each guest to make a concluding statement.
Cheng Zengjiang: In the biomedical field, there is limitless space for innovation. And when innovation is at its best, let's make innovations and improve the quality of life for all of us.
Finance & Economics Annual Meeting 2018: Forecast & Strategy Organized by Caijing Magazine and Caijing Net and held in Beijing from November 28 to November 30.
(Guest opinion according to the site to speak, without the spokesman himself confirmed)
[Editor: Yan started PQ016]